Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.

The breast cancer treatment market is rapidly growing, driven by advances in technology, personalized therapies and early diagnosis efforts.

The results emphasize the importance of PARP inhibitors in BRCA-mutated breast cancer, particularly in triple-negative breast ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Market OverviewBreast cancer remains one of the most prevalent forms of cancer worldwide, affecting millions of individuals ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

Pfizer enters exclusive global, ex-China licensing pact with 3SBio for development, manufacturing & commercialization of SSGJ-707: New York Tuesday, May 20, 2025, 14:30 Hrs [IST] ...